Drug: Tekturna (aliskiren)
Approval Date: March 5, 2007
Scoop: Tekturna is the first in a new class of drugs called direct renin inhibitors, which target an enzyme responsible for triggering a process that can contribute to high blood pressure. Novartis hopes that Tekturna will eventually replace the company's blockbuster drug Diovan--which does $4.22 billion in annual sales--when the patent on that drug expires.
FDA approves Novartis' Tekturna. Report
Image: Tekturna packaging